Tag
mdma
- New Zealand begins prescribing MDMA for severe PTSD treatment
- Puerto Rico governor signs executive order for psychedelic therapy research
- CNS drug specialist Jupiter Neuro signs MDMA deal with PharmAla Biotech
- Deutsche Bank initiates bullish coverage of psychedelics company AtaiBeckley
- Non‑profit Heroic Hearts publishes psychedelics guide for veterans
- Veterans and psychedelic therapy advocates back Freedom to Heal Act
- 'ATMA CENA' will soon have 13 psychedelics clinics operating in Canada
- Optimi Health produces largest-ever batch of MDMA capsules
- Edmonton's new psychedelic therapy clinic helps residents soothe the winter blues
- The Best of 2024: A Mugglehead roundup
- If you thought garden gnomes were trippy, just wait till you hear this
- Denver prepares to host psychedelic therapy expo in November
- Kingston psychedelics complex celebrates grand opening
- Investors wince as FDA panel rejects proposal to approve 'molly' for PTSD therapy
- Optimi Health gets psychedelics import permit for Mind Medicine Australia shipment
- Psychedelic drugs for therapy: history, effectiveness, legal status
- U.S. invests millions in psychedelics research to treat chronic pain in older adults
- Portland VA opens psychedelic therapy clinic for mental health and substance use disorders
- ATMA CENA opens Alberta psychedelic therapy clinics, Ontario locations to follow
- Incannex and partner Clarion open Australia's first psychedelic therapy clinic in Melbourne
- PharmAla Biotech ships first batch of MDMA and psilocybin to be used as medicines in Australia
- California startup Tactogen gets U.S. patent for MDMA derivatives
- MDMA-assisted therapy significantly reduces moderate to severe PTSD symptoms
- PharmAla Biotech lists on the OTCQB middle-tier venture market
- CBSA busts 3.3 tonnes of chemicals used to manufacture MDMA
- PharmAla Biotech receives guidance on new MDMA-like drug for PTSD and Autism
- Majority of Americans support regulating psychedelics: UC Berkeley survey
- UC San Diego receives US$1.5M for cognitive research on DMT
- PharmAla Biotech secures first purchase order for GMP LaNeo MDMA in Australia
- FDA publishes first draft guidance document for psychedelics research
- Optimi Health to supply MDMA for new psychedelic therapy program at Numinus clinics
- Mind Medicine Australia to supply medical psilocybin and MDMA for clinical trials at no cost
- Optimi Health completes harvesting psilocybin mushrooms for Australia-bound medical extract
- PharmAla Biotech first to get Special Access Program authorization for its MDMA
- Optimi Health enters $1.2M psilocybin distribution agreement
- PharmAla Biotech and Vitura Health form joint psychedelics venture in Australia
- Incannex orders psilocybin and MDMA from PharmAla Biotech
- International psychedelics market to reach US$8.3B by 2027: ReportLinker
- Mydecine's MDMA with rapid onset and a short duration shows promising results
- PharmAla Biotech and Filament Health partner to release MDMA capsules
- Dutch government establishes MDMA research commission
- Optimi Health secures MDMA and psilocybin distribution agreement in Australia
- PharmAla Biotech signs agreement to sell clinical-grade MDMA in Australia
- Optimi Health submits clinical trial application after developing proprietary MDMA drug
- Australia re‑classifies MDMA and psilocybin to be prescribed as medicine
- Calgary’s ATMA launches psychedelic-assisted therapy training course for physicians
- PharmAla Biotech gets Health Canada approval to export large MDMA shipment to the U.K.
- U.S. senators introduce bill to improve access to psilocybin and MDMA
- PsyCan aims to be ‘go‑to’ psychedelics industry organization, receives support from lawmakers
- Psychedelic drugs market awaits nearly 100% revenue expansion by 2026 end: Fairfield